Wyoming

Wyoming

NO Registered Patient Population

0% of Total Population Represented by Patients

0 Total Medical Retail Locations Currently in Operation

N/A Ratio of Patients to Retail Location

CBD treatment is legal in Wyoming. The program limits patients with intractable epilepsy to cannabidiol preparations with 0.3 percent or less THC, in compliance with USDA hemp standards but does not authorize in-state production in compliance with those rules.

Patient Rights and Civil Protection	45/100
Arrest Protection 24/40 Affirmative Defense 9/15 Parental Rights Protections 0/10 DUI Protections 0/5 Employment Protections 0/5 Explicit Privacy Standards 7/7 Housing Protections 0/5 Does Not Create New Criminal Penalties for Patients 5/5 Organ Transplants 0/5 Reciprocity 0/3
Access to Medicine	13/100
Allows Distribution Programs 0/40 – Allows Access to Dried Flowers 0/15 – Allows Delivery 0/5 – No Sales Tax or Reasonable Sales Tax 0/5 – Allows for a Reasonable Number of Dispensaries 0/5 – Does Not Require Vertical Integration 0/2 – Ownership/Employment Restrictions 0/2 – Provisions for Labor Standards 0/2 – Environmental Impact Regulations 0/2 – Choice of Dispensary Without Restrictions 0/2 Noncommercial Cultivation 0/20 – Personal Cultivation 0/15 – Collective Gardening 0/5 Explicit Right to Edibles/Concentrates/Other Forms 3/10 Does not Impose Bans or Limits on THC 2/10 Does not Impose Bans on CBD 8/10 Local Bans/Zoning 0/10
Ease of Navigation	44/100
Comprehensive Qualifying Conditions 20/50 Adding New Conditions 0/10 – Law/Regulations Allow for New Conditions 0/5 – System Works for Adding New Conditions 0/5 Reasonable Access for Minors 6/10 Reasonable Caregiver Background Checks 4/4 Number of Caregivers 1/2 Patient/ Practitioner- Focused Task Force or Advisory Board 0/2 Reasonable Fees (Patients and Caregivers) 6/10 Allows Multiple-Year Registrations 0/2 Reasonable Physician Requirements 5/5 Does Not Classify Cannabis as a Medicine of Last Resort 2/5
Functionality	27/100
Patients Able to Access Medicine at Dispensaries or by Cultivation 0/50 No Significant Administrative or Supply Problems 10/15 Patients Can Receive Legal Protections Within Reasonable Time Frame of Doctor's Recommendation 7/10 Reasonable Possession Limits 5/5 Reasonable Purchase Limits 0/5 Allows Patients to Medicate Where They Choose 3/5 Covered by Insurance/State Health Aid 0/3 Financial Hardship (Fee Waivers/Discount Medicine) 2/7
Consumer Safety and Provider Requirements	0/100
Dispensing 0/25 Staff Training 0/5 Standard Operating Procedures 0/5 – Facility Sanitary Conditions 0/1.25 – Storage Protocols 0/1.25 – Reasonable Security Protocols 0/1.25 – Inventory Control 0/1.25 Recall Protocol and Adverse Event Reporting 0/5 Product Labeling 0/5 – Product Contents, Including Source Material Identification 0/1.67 – Allergens 0/1.67 – Potency/Compound Identification 0/1.67 Required Testing 0/5 – Active Compound Identification 0/1.67 – Contaminants 0/1.67 – Potency 0/1.67 Grow/Cultivation 0/25 Staff Training 0/5 Standard Operating Procedures 0/5 – Facility and Equipment Sanitary Conditions 0/0.71 – Workforce Safety Protocols 0/0.71 – Storage Protocols (Short-Term and Long-Term Storage) 0/0.71 – Reasonable Security Protocols 0/0.71 – Batch and Lot Tracking 0/0.71 – Disposal/Waste 0/0.71 – Water Management 0/0.71 Pesticide Guidance 0/5 – Pesticide Guidance 0/2.5 – Pesticide Labeling 0/2.5 Required Testing 0/5 – Active Ingredient Identification 0/1.25 – Contaminants 0/1.25 – Potency 0/1.25 – Sample Retention 0/1.25 Recall Protocol and Adverse Event Reporting 0/5 Manufacturing 0/25 Staff Training 0/5 Standard Operating Procedures 0/5 – Facility and Equipment Sanitary Conditions 0/1 – Workforce Safety Protocols 0/1 – Storage Protocols 0/1 – Reasonable Security Protocols 0/1 – Batch and Lot Tracking 0/1 Product Labeling 0/5 – Product Contents, Including Source Material Identification 0/1.67 – Allergens 0/1.67 – Potency and Compound Information 0/1.67 Required Testing 0/5 – Active Ingredient Identification 0/1 – Contaminants 0/1 – Potency 0/1 – Shelf Life Testing 0/1 – Sample Retention 0/1 Recall Protocol and Adverse Event Reporting 0/5 Laboratory Operations 0/25 Staff Training 0/5 Method Validation in Accordance with AHP Guidelines 0/5 Result Reporting 0/5 Independent or Third Party 0/5 Standard Operating Procedures and Protocols 0/5 – Equipment and Instrument Calibration 0/0.83 – Sample Tracking 0/0.83 – Facility and Equipment Sanitary Conditions 0/0.83 – Disposal/Waste 0/0.83 – Storage Protocols 0/0.83 – Workforce Safety Protocols 0/0.83
Covid Response	0/20
Delivery Available? 0/6 Curbside Pickup Available? 0/2 Medical Cannabis Essential? 0/7 Telemedicine Available? 0/5
Excerpted from ASA's 2020 State of the States Report.

Becoming a Patient in Wyoming

Recommending Cannabis in Wyoming

History of Medical Cannabis in Wyoming

Policy Recommendations Wyoming